BioRegenx, Inc.
BRGX
$0.0115
-$0.0005-4.17%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 91.53% | -7,068.13% | 84.32% | -497.78% | -1,271.85% |
| Total Depreciation and Amortization | -97.52% | 47,775.00% | 47,775.00% | 72,416.67% | 41,608.33% |
| Total Amortization of Deferred Charges | -86.61% | -- | -- | -- | -- |
| Total Other Non-Cash Items | -96.02% | 6,604.94% | -111.64% | -- | -- |
| Change in Net Operating Assets | -18.69% | 155.09% | 1,102.44% | 351.00% | 324.86% |
| Cash from Operations | 136.15% | 95.36% | 88.99% | 50.86% | 69.11% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 101.35% | -- | -- | -- |
| Cash from Investing | -- | 101.35% | -- | -- | -- |
| Total Debt Issued | -- | -42.31% | -20.22% | -25,587.50% | 37,400.00% |
| Total Debt Repaid | 40.23% | 48.17% | 43.72% | 1,650.00% | 89.94% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -103.68% | -101.34% | -60.03% | -4,640.56% | 70.65% |
| Foreign Exchange rate Adjustments | -310.00% | 544.44% | -- | -96.64% | -79.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 325.00% | -117.36% | 107.59% | 74.65% | 93.31% |